Here is a comprehensive overview of Liver Surface Nodularity (LSN).
Liver Surface Nodularity (LSN)
Pathophysiology
Progressive hepatic fibrosis causes the formation of fibrotic bands and regenerative nodules throughout the liver parenchyma. As fibrosis worsens, these changes distort the normally smooth liver capsule into an irregular, bumpy ("nodular") contour. LSN is therefore a morphological marker that reflects the degree of underlying fibrosis - the more advanced the fibrosis, the greater the surface irregularity.
Detection Methods
1. Ultrasound (Qualitative)
The most accessible method. Using a high-frequency linear array transducer directly on the liver surface, an irregular/nodular contour can be identified visually. This is one of the classic sonographic signs of cirrhosis, alongside:
- Right lobe atrophy with compensatory left lobe/caudate hypertrophy
- Parenchymal inhomogeneity
- Signs of portal hypertension (splenomegaly, varices, ascites)
However, ultrasound detection of nodularity is subjective and operator-dependent, with moderate sensitivity and specificity for cirrhosis detection.
Here is the sonographic appearance of liver surface nodularity in a cirrhotic liver (arrows indicate the bumpy contour, asterisk = ascites):
Yamada's Textbook of Gastroenterology, 7th ed. - Sonogram with high-frequency linear transducer showing nodular contour of cirrhotic liver (arrows) with moderate ascites (*).
2. CT - Quantitative LSN Score (Primary Method)
CT allows software-based quantification of liver surface nodularity, producing the LSN score (also called the "Liver Score"):
How it is measured:
- Imaging software automatically detects the liver surface outline on axial CT slices
- LSN score = average distance between the detected liver surface and a smoothed polynomial "best-fit" line
- 10 contiguous CT slices are evaluated (total coverage: 80-100 cm)
- Final score = average of all slice scores, expressed in tenths of a millimeter
- Processing time: <2 minutes
- Works on non-contrast and contrast-enhanced CT
Score ranges:
| LSN Score | Interpretation |
|---|
| ~1.30 | Normal liver (F0) |
| ~1.45 | Early fibrosis (F1) |
| >1.48 | Suggests F2+ (NAFLD cut-off) |
| ~1.67+ | Advanced fibrosis (F2-F3) |
| 1.5-5.0 | Typical clinical range |
| >5.0 | Severe/decompensated cirrhosis |
Diagnostic Accuracy for Fibrosis Staging (CT-based)
From HCV and NAFLD studies (AUC values):
| Target | AUC |
|---|
| Early fibrosis (>F2) | 0.88-0.90 |
| Advanced fibrosis (>F3) | 0.89-0.93 |
| Cirrhosis (F4) | 0.90-0.96 |
- In NAFLD specifically: cut-off LSN >1.48 differentiates F1 from F2/F3 with sensitivity 83%, specificity 73%, AUROC 0.788
- Accuracy further improves when combined with FIB-4 index (age + AST + ALT + platelet count)
Clinical Applications
- Non-invasive fibrosis staging in chronic liver disease (HCV, NAFLD/NASH, alcohol-related liver disease)
- Substaging of cirrhosis - the LSN score is a strong predictor of hepatic decompensation (variceal bleeding, encephalopathy, ascites) and death (Smith et al., Radiology 2017)
- Portal hypertension detection - LSN correlates with hepatic venous pressure gradient (Sartoris et al., Radiology 2018)
- Reducing liver biopsies - high negative predictive value for ruling out advanced fibrosis
- Retrospective staging from existing CT images (no additional scan needed)
Reliability
| Parameter | Value |
|---|
| Inter-observer reliability (ICC) | 0.94 (CV 9%) |
| Test-retest reliability (ICC) | 0.82 (CV 12%) |
| Software vs. visual scoring ICC | 0.84 vs. 0.61 |
| Technical failure rate | 0-3.9% |
Limitations and Contraindications
| Limitation | Detail |
|---|
| Ionizing radiation | Requires CT scan |
| Ascites | Fluid obscures liver surface detection |
| Very low BMI | No perihepatic fat = technical failure |
| Limited validation | Mainly HCV and NAFLD; less data for other CLD causes |
| Pregnancy | Relative contraindication (radiation) |
| Software requirement | Needs dedicated post-processing software |
MRI-Based LSN
Emerging MRI-compatible LSN software has been developed (Hanaoka et al., 2019) that applies the same measurement principle to MRI images, offering the advantage of no ionizing radiation. Validation is still ongoing before clinical implementation.
Context Among Non-Invasive Fibrosis Tools
| Tool | Type | Modality |
|---|
| LSN score | Quantitative morphology | CT/MRI |
| LSM (FibroScan) | Liver stiffness | Ultrasound elastography |
| MR Elastography | Liver stiffness | MRI |
| FIB-4 | Serum biomarker | Blood |
| NAFLD Fibrosis Score | Serum biomarker | Blood |
| BARD score | Serum biomarker | Blood |
A 2024 review (
Zheng et al., Abdom Radiol 2024, PMID 38372765) places LSN among the most promising quantitative imaging biomarkers for cirrhosis, alongside elastography, extracellular volume fraction, and diffusion-weighted imaging parameters.